MIMEDX Appoints Matt Notarianni as Head of Investor Relations

/EIN News/ — Experienced finance and communications leader focused on healthcare to strengthen and expand relationships with investment community

MARIETTA, Ga., Oct. 04, 2022 (GLOBE NEWSWIRE) — MiMedx Group, Inc. (NASDAQ: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced the appointment of Matt Notarianni as Head of Investor Relations (IR), effective immediately. Mr. Notarianni joins MIMEDX with over 15 years of experience on Wall Street and in healthcare IR, most recently as Head of IR for Cerus Corporation.

“I’m thrilled to welcome Matt to MIMEDX,” said K. Todd Newton, Acting General Manager of MIMEDX. “Matt’s breadth of experience in health-focused financial services, IR and strategy roles makes him an ideal candidate to amplify the MIMEDX story with the investment community. I look forward to working with Matt to continue to evolve our IR strategy and increase our level of engagement with current and potential investors and analysts.”

“I am delighted to join MIMEDX at this critical time for the company,” said Mr. Notarianni. “As a pioneer and leader in placental biologics, MIMEDX has a strong business with a number of exciting growth opportunities ahead. I look forward to working with the management team and Board of Directors to help realize these opportunities and communicate the company’s progress to the investment community.

Jack Howarth, MIMEDX’s Senior Vice President of Investor Relations, will continue to support MIMEDX’s IR function until his expected retirement at the end of this year.

“On behalf of the entire MIMEDX team, I would like to thank Jack for his many contributions to the company over the years,” continued Mr. Newton. “With a career spanning over four decades, we wish Jack a wonderful retirement.”

Prior to this role at Cerus, Mr. Notarianni worked at Immucor, Inc. from 2012 to 2021, most recently serving as Senior Director, Corporate Development and External Communications. He began his career as an equity research analyst at Robert W. Baird & Co., covering the life science tools and diagnostics space. Mr. Notarianni received his Bachelor of Business Administration from Marquette University.


MIMEDX is a transformational placental biologics company, which develops and distributes placental tissue allografts with patented and proprietary processes for multiple healthcare sectors. As a pioneer in placental tissue engineering, we have both commercial activity, focused on the needs of patients with acute and chronic non-healing wounds, and a promising late-stage pipeline aimed at reducing pain and improving function of patients with degenerative musculoskeletal disorders. conditions. We derive our products from human placental tissues and process these tissues using our proprietary methods, including the PURION® treat. We use current good tissue practices, current good manufacturing practices and terminal sterilization to produce our allografts. MIMEDX has supplied over two million allografts, through direct and consignment shipments. For more information, please visit www.mimedx.com.


Matt Notarianni
Investor Relations

main logo

Comments are closed.